Skip to content

Study · Case report or series · n = 1 · 2023

2 results

Liraglutide-Induced Pancreatitis: A Case Report and Literature Review.

Javed H, Kogilathota Jagirdhar GS, Kashyap R, Vekaria PH

Cureus28 Apr 2023Cited by 9 (Europe PMC)

PMID37252522 (opens in a new tab)PMCIDPMC10225244 (opens in a new tab)DOI10.7759/cureus.38263 (opens in a new tab)PepBankPUB-37252522
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Liraglutide is an anti-diabetic medication used for the treatment of type 2 diabetes mellitus, obesity, and chronic weight management. It is a glucagon-like peptide-1 (GLP-1) agonist that helps reduce postprandial hyperglycemia for up to 24 h after administration. It stimulates endogenous insulin secretion according to glucose levels, and also delays gastric emptying and suppresses prandial glucagon secretion. Some of the common complications associated with liraglutide include hypoglycemia, headache, diarrhea, nausea, and vomiting. Uncommon adverse effects include pancreatitis, kidney failure, pancreatic cancer, and injection site reactions. In this article, we discussed a case of a 73-year-old male with a history of uncontrolled type 2 diabetes mellitus on long-term insulin and liraglutide who presented with abdominal pain, subjective fevers, dry heaves, tachycardia, and mildly reduced oxygen saturation. The patient was diagnosed with pancreatitis on the basis of laboratory and imaging findings. Liraglutide was discontinued, and the patient received supportive care with significant clinical improvement. The use of GLP-1 inhibitors has been increasing not only for diabetes mellitus management, but also for its promising effect on weight management. The literature review endorses our case report findings, and also discusses other complications of liraglutide. Therefore, we recommend to be cognizant of these side-effects upon starting liraglutide.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 73-year-old man with type 2 diabetes on long-term liraglutide, pancreatitis was diagnosed on laboratory and imaging findings.

    In plain wordsA 73-year-old man with type 2 diabetes on liraglutide was diagnosed with pancreatitis.

    Peptide
    Liraglutide
    Outcome
    IncreasePancreatitis
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient was diagnosed with pancreatitis on the basis of laboratory and imaging findings.
    1 context sentence
    Summary · context
    In this article, we discussed a case of a 73-year-old male with a history of uncontrolled type 2 diabetes mellitus on long-term insulin and liraglutide who presented with abdominal pain, subjective fevers, dry heaves, tachycardia, and mildly reduced oxygen saturation.
  2. 02HumanCase report or seriesSafety outcome

    In the same patient, liraglutide was discontinued and supportive care led to significant clinical improvement.

    In plain wordsAfter liraglutide was stopped and supportive care given, the patient improved significantly.

    Peptide
    Liraglutide
    Outcome
    DecreaseClinical course after liraglutide discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide was discontinued, and the patient received supportive care with significant clinical improvement.
    1 context sentence
    Summary · context
    In this article, we discussed a case of a 73-year-old male with a history of uncontrolled type 2 diabetes mellitus on long-term insulin and liraglutide who presented with abdominal pain, subjective fevers, dry heaves, tachycardia, and mildly reduced oxygen saturation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.